NAD+ Peptide: Injection Dosage Chart, Frequency and What the Evidence Supports

Start with what most pages selling NAD+ will not say in the first paragraph. NAD+ is not a peptide. It is a coenzyme, built from a nicotinamide and an adenine nucleotide, with no amino acid chain in it at all. It sits on peptide vendor shelves because it arrives in the same lyophilised vials, is reconstituted the same way and is bought by the same people. The category is a distribution accident rather than a chemical family.

That matters for dosing, because it explains why NAD+ numbers look enormous next to everything else in the drawer. Peptides are dosed in micrograms. NAD+ is dosed in tens or hundreds of milligrams, a thousandfold change of scale. What follows is the whole picture people mean when they search for the NAD+ peptide: what it is, the dosage chart, routes, ranges, the flush, what the human research supports and the arithmetic. For how NAD+ compares against other options, see the peptides for energy guide and the longevity ranking.

Is NAD+ a Peptide? The Short Answer and the Long One

No, and nothing about its structure makes it one. A peptide is a chain of amino acids joined by peptide bonds. NAD+ is nicotinamide adenine dinucleotide: two nucleotides, one carrying nicotinamide and one carrying adenine, joined through a pair of phosphate groups. There is no amino acid in it and no peptide bond anywhere. The same goes for the precursors sold beside it, NMN and NR, which are nucleotide and nucleoside chemistry rather than protein chemistry.

So why does so much of the search traffic ask for the NAD+ peptide? Because of where it is sold. NAD+ arrives in the same lyophilised vial with the same rubber stopper, is reconstituted with the same bacteriostatic water, is drawn into the same insulin syringe and sits on the same research chemical vendor page as BPC-157 and tesamorelin. Buyers learned the category from the shelf rather than from the chemistry, and no vendor had a reason to correct them. "NAD+ peptide" is a shopping label, not a classification, and this page uses it the way readers do while being clear about what it means.

Insisting on the distinction earns its keep in one place: dose scale. The peptides on that shelf are dosed in micrograms and low milligrams, 100mcg of ipamorelin, 250mcg of BPC-157, 1 to 2mg of GHK-Cu. NAD+ is dosed in tens to hundreds of milligrams. Read an NAD+ figure with peptide intuition and it looks like a typo. Read a peptide figure with NAD+ intuition and you are out by a factor of a thousand. Keeping the two categories apart is not pedantry, it is the arithmetic.

There is a second consequence. Because NAD+ is not a peptide and does not act on a receptor, none of the peptide specific reasoning carries over. There is no receptor to desensitise, no pulsatility argument for timing a dose against sleep, no growth hormone axis to cycle around. Whatever reasons exist to cycle NAD+ are about cost, tolerance and the flush rather than pharmacology.

NAD+ Peptide Dosage Chart

This is the chart people come here for, so it sits near the top rather than at the end. Every figure in it describes what circulates in clinic practice and community protocols. None of it is the output of a dose finding study, because no dose finding study of injected NAD+ has been published. Read it as a map of practice presented as research use information, not as a recommendation.

NAD+ injection dosage per day

The honest answer to the per day question is that most subcutaneous schedules do not have a per day number, because they are not daily. The common pattern is two or three sessions a week. Where people do inject every day they drop the size of each dose to roughly 20 to 50mg, which keeps the weekly total in the same place as the intermittent schedule while making each push milder. If you want one number to hold in your head, 50mg on an injection day is the middle of the range, and the days between injections are part of the protocol rather than missed doses.

NAD+ injection dosage per week

The weekly total is the more useful frame for a schedule that is intermittent by design. Totals in circulation cluster between 100 and 300mg subcutaneously, assembled out of two or three sessions. A 1,000mg vial therefore covers between three and ten weeks depending where in that range you sit, which is worth knowing before buying, because reconstituted NAD+ is not stable for months. Higher weekly totals are quoted and reach past 1,000mg, but nothing published shows the extra milligrams doing anything, and the flush scales with the size of each push.

NAD+ injection dosage and frequency together

Dose and frequency are not independent knobs, and the order you turn them in is the single most practical thing on this page. The flush tracks the size and speed of a single push. An extra session at the same size does not make it worse. So when a protocol goes up, frequency moves first: two sessions become three before 50mg becomes 75mg. Going the other way, someone struggling with the flush at 100mg twice weekly is usually better served by 50mg four times weekly than by abandoning it, since both land on the same 200mg week.

What NAD+ Actually Does

In plain English, NAD+ is the cell's electron shuttle. Almost every reaction that extracts energy from food hands off electrons, and NAD+ carries them to the electron transport chain where the cell turns them into usable energy. It cycles between an oxidised and a reduced form rather than being consumed, which makes it a coenzyme and not a fuel. Separately, it is the substrate used up by the sirtuins and by the PARP enzymes, involved in DNA repair.

The age related decline is the best supported part of the picture. Levels do fall. What is far less settled is whether raising circulating NAD+ by injection changes anything a person notices or a test measures, and that is the gap most marketing walks over. NAD+ is a large charged molecule, so uptake of the intact coenzyme is questionable. It may simply be broken down and rebuilt inside the cell, in which case injecting the finished article offers nothing over a precursor.

Subcutaneous Versus Intravenous NAD+

Intravenous NAD+ is a clinic procedure: several hundred milligrams over a slow infusion lasting much of an afternoon, with the rate dialled down whenever the recipient becomes uncomfortable. It is slow because speed, not total quantity, produces the unpleasant sensations.

Subcutaneous NAD+ is a self administered injection of a much smaller quantity into abdominal fat, absorbed over a period rather than delivered straight to circulation. It trades peak exposure for convenience and cost, and the doses reflect that. No published comparison of the two routes against a meaningful endpoint exists, so the choice is practical rather than evidence led. One consequence is worth stating plainly: an IV figure delivered subcutaneously in a single push is a common and avoidable mistake. The routes do not share a range.

The argument each route makes is easy to state. Intravenous puts the whole dose into circulation on a schedule the clinic controls, which is the only way anyone has studied NAD+ in people, and it is also the reason it costs what it costs: the price is the chair, the hours and the supervision rather than the material. Subcutaneous costs a small fraction of that per session, fits around a normal week and gives a slower absorption profile, at the cost of never having been studied at all. A third route, intramuscular, turns up in some clinic protocols at doses similar to the subcutaneous ones; it has the same evidence base as subcutaneous, which is to say none, and a deeper injection with no obvious advantage.

What nobody can tell you is which route, if either, gets more of the intact coenzyme into cells. That is the question the uptake problem above puts at the centre of the whole category, and neither route has an answer to it.

Subcutaneous Dose Ranges and Frequency

No dose finding trial establishes a subcutaneous NAD+ dose. The ranges below come from clinic practice and community protocols, so they describe what people do rather than what has been shown to work. They are consistent across sources, but a convention is not evidence.

The shape is consistent too. Subcutaneous NAD+ is dosed intermittently rather than daily: typically 50 to 100mg per session, two or three times a week, for a weekly total of roughly 100 to 300mg. Wider ranges reaching 500mg per session are quoted, and no dose response curve suggests the upper end achieves more.

Notice which variable moves first. Frequency rises before dose, because a larger single push causes the discomfort and an extra session does not.

The Flush, and Why Slow Administration Is the Standard Answer

This is the best documented practical fact about NAD+ injections. Pushed quickly, NAD+ commonly produces a strong immediate sensation: flushing, a feeling of pressure or tightness in the chest or head, and often nausea. It arrives within seconds, peaks fast and fades over a few minutes once administration stops. It is close to universal at speed rather than idiosyncratic, which is why IV clinics infuse slowly.

The mechanism is not fully characterised, but the practical rule holds: the sensation tracks the rate of administration far more closely than the total dose. The same 100mg that is intolerable pushed in three seconds is often unremarkable delivered over a minute. So the standard answer has two parts. Push slowly, taking thirty to sixty seconds rather than treating it like a peptide shot, and pause if the sensation builds. Then titrate, starting low enough to be boring and raising only once the previous step is comfortable. The injection guide covers site rotation, which matters more here because the volumes are larger.

Reconstitution and Storage

NAD+ is reconstituted like a lyophilised peptide, covered in the reconstitution guide. Three points are specific to it.

Volume. Vials are commonly 500mg or 1000mg, so the water volume must be chosen so that a dose fits inside a one millilitre syringe.

Stability. NAD+ in solution is not indefinitely stable. Reconstituted vials belong in the refrigerator, protected from light, and the solution is treated as a short lived preparation of a few weeks rather than something kept for months. Discard one that has visibly discoloured. The storage guide covers the general rules.

Sterility. A 1000mg vial at 100mg a session is ten needle entries through one stopper across weeks. Swab it every time, and use bacteriostatic rather than sterile water.

Milligrams to Syringe Units, With a Worked Example

Concentration is vial milligrams divided by millilitres of water added. Volume per dose is the dose divided by that concentration. Units are that volume multiplied by 100 on a U-100 insulin syringe, where 100 units is one full millilitre.

Worked example. A 500mg vial plus 5mL of bacteriostatic water gives 100 mg/mL. A 50mg dose is 50 divided by 100, so 0.5mL, which reads as 50 units. A 100mg dose from the same vial is 1.0mL, the entire syringe, which leaves no room for error and makes a slow push awkward. Reconstituting that vial in 2.5mL instead gives 200 mg/mL, at which 100mg reads as 50 units.

For NAD+ the higher concentration usually wins, because a large subcutaneous volume is uncomfortable in itself. The NAD+ dosage calculator runs this for any vial and water combination.

What the Human Research Actually Shows

Almost all of it is about precursors rather than about injected NAD+. That one sentence is probably the most useful thing on this page, because the studies people cite when selling NAD+ injections are usually oral NR or NMN trials with the route quietly dropped.

Oral nicotinamide riboside has the clearest human pharmacokinetics. Trammell and colleagues (Nature Communications, 2016) ran the first human study and showed that single oral doses raise blood NAD+ measurably and dose dependently. Martens and colleagues (Nature Communications, 2018) followed with six weeks at 1,000mg a day in healthy middle aged and older adults: whole blood NAD+ rose by roughly 60 percent and the regimen was well tolerated, with a blood pressure signal in a subgroup that the authors themselves flagged as exploratory rather than a result.

Then it gets mixed, which is the part the marketing skips. Elhassan and colleagues (Cell Reports, 2019) gave aged men 1,000mg of NR a day for three weeks and found blood NAD+ metabolites rose while skeletal muscle NAD+ did not change significantly, a problem if muscle was the tissue you cared about. Dollerup and colleagues (American Journal of Clinical Nutrition, 2018) ran 2,000mg a day for twelve weeks in obese insulin resistant men and found no improvement in insulin sensitivity, mitochondrial function or the other prespecified metabolic endpoints. NMN has one frequently cited positive result, from Yoshino and colleagues (Science, 2021), who gave 250mg a day for ten weeks to postmenopausal women with prediabetes and reported improved muscle insulin sensitivity in a small trial with a single primary outcome.

For NAD+ itself there is a pilot, and it is intravenous. Grant and colleagues (Frontiers in Aging Neuroscience, 2019) infused 750mg over six hours into a small group of healthy men and tracked the plasma and urine metabolome. The finding that matters to a reader of this page is the timing: plasma NAD+ did not move appreciably for the first couple of hours, and the metabolite pattern indicated that a good deal of the dose was being processed and excreted rather than cleanly raising the circulating pool. One small pilot of pharmacokinetics, not a trial of an outcome.

Of subcutaneous NAD+, the route this entire page is about, we could find no published human trial on PubMed as of September 2026. No dose finding study, no pharmacokinetic study, no controlled outcome study. That is the gap every subcutaneous protocol sits inside, and it is the reason the chart near the top of this page is labelled as a description of practice rather than as evidence.

NAD+ Peptide Versus NMN and NR

NMN and NR are oral precursors: the cell takes them in and builds NAD+ from them through its own salvage pathway. Injectable NAD+ delivers the finished coenzyme to circulation instead. The argument for injecting is that it skips the digestive tract. The argument against is the uptake question above. Both are mechanistic rather than settled, because the head to head trial does not exist.

The practical asymmetry is harder to ignore. An oral precursor needs no needles, no reconstitution and no refrigeration, produces no flushing, and costs a fraction as much. That is not an argument that injectable NAD+ is useless. It is an argument that the burden of proof sits on the more expensive and less comfortable option, and has not been met, which is where the energy guide lands too.

Where the Arithmetic and the Expectations Go Wrong

• Carrying peptide intuition across. A figure in milligrams that looks like a typo usually is not.
• Using an IV figure subcutaneously. A several hundred milligram infusion dose pushed under the skin in one go is the most predictable way to have a bad time.
• Pushing fast and concluding NAD+ is intolerable. Someone who pushed 100mg in a few seconds has learned something about speed, not about the compound.
• Escalating because nothing was felt. Cellular metabolism and DNA repair are not perceptible. A dose increase after a week answers an endpoint that was never going to show anything.
• Buying the marketing. The established facts are that levels decline and the coenzyme is essential. Past that is hypothesis.

Key Takeaways

• NAD+ is a coenzyme, not a peptide, and the phrase "NAD+ peptide" describes the shelf it is sold on rather than its chemistry
• Doses are in milligrams, a thousandfold scale change from peptide dosing
• Subcutaneous protocols cluster at 50 to 100mg, two to three times weekly, from practice rather than trials
• Flushing, pressure and nausea are common when NAD+ is pushed quickly, and slow administration is the answer
• Start low, raise frequency before dose, and treat the first fortnight as tolerance testing
• Oral precursors reach the same pathway far more cheaply, and the case for injecting is unsettled
• The human trials people cite are almost all oral NR and NMN studies. No published trial of subcutaneous NAD+ exists

The longevity guide ranks NAD+ against the alternatives, and the Epithalon page covers the one compound there with long term human follow up. This is research use information, not medical advice.

Frequently Asked Questions

Is NAD+ a peptide?

No. A peptide is a chain of amino acids joined by peptide bonds, and NAD+ has neither. It is nicotinamide adenine dinucleotide, two nucleotides linked through a pair of phosphate groups. People search for "NAD+ peptide" because it is sold on peptide vendor shelves, arrives in the same lyophilised vial and is reconstituted the same way. The label comes from the shop, not the chemistry, and the difference matters because NAD+ is dosed in tens to hundreds of milligrams where peptides are dosed in micrograms.

What is the usual NAD+ injection dosage per day?

Most subcutaneous protocols are not daily at all. The common pattern is 50 to 100mg on two or three separate days, and people who do inject daily tend to use the low end, around 20 to 50mg. None of these figures comes from a dose finding trial. They come from clinic practice and community protocols, so the range describes what is done rather than what is correct.

What is the right NAD+ injection dosage and frequency?

There is no established answer, because the studies that would settle it have not been run. The widely used shape is two to three subcutaneous doses a week, starting near 25mg and rising only if the injection is comfortable. Frequency is usually adjusted first, because a larger single dose is what produces the flushing and pressure, while more sessions at the same size do not.

What is a typical NAD+ injection dosage per week?

Weekly totals in circulation usually fall between 100 and 300mg subcutaneously, assembled from two or three sessions. Higher totals are discussed, and the wider range quoted reaches 500mg, but no published dose response curve shows that more delivers more. A weekly total is a more useful frame than a per day number, because the schedule is intermittent.

What are the benefits of NAD+ injections?

What is established is that NAD+ is essential to energy metabolism and DNA repair, and that levels decline with age. What is not established is that injecting it produces a specific outcome in a healthy person. Reports of improved energy and clearer thinking are uncontrolled and susceptible to expectation. The honest summary is a solid mechanism, a real decline, and an unsettled case that this route changes anything measurable.

How much do NAD+ injections cost?

Two very different markets sit behind that question. Clinic administered intravenous infusions are priced per session and are by far the most expensive way to buy NAD+, because the cost is mostly the chair, the time and the supervision. Self administered vials cost a fraction of that per milligram, though NAD+ is dosed in hundreds of milligrams, so material cost stays high next to most of the shelf.